Q4 2024
Released Mar 6, 2025, after the close
10-K filed Mar 24, 2025, 83 days after period end · 0001641172-25-000234
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.87M$3.87M derived+18.9% vs Q4 2023+10.0% vs Q3 2024
Net Income$349.00K$349.00K derivedN/M vs Q4 2023+90.7% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$2,475,000+22.5%
Operating Incomederived$317,000N/M
Operating Cash Flowderived$1,304,000N/M
Free Cash Flowderived$1,304,000—
Margins · derived
Gross margin64.0%+1.8 pt vs Q4 2023
Operating margin8.2%+28.1 pt vs Q4 2023
Net margin9.0%+29.1 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $3.87M | $3.25M | $2.56M | $2.64M |
| Net Income | $349.00K | -$654.00K | -$771.00K | -$982.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR